Sovremennoe lechenie revmatoidnogo artrita: rekomendatsii i real'naya praktika


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

To date, the treatment of rheumatoid arthritis (RA) has some success. The emergence of new diagnostic criteria 2010 for RA, implementation of the principles of controlled treatment in practice - strategy of treatment of RA to achieve the goal, the emergence of new forms of previously used disease modifying anti-rheumatic drugs (DMARDs) and new generation preparations (genetically engineered biological agents and the targeted synthetic DMARDs - tofacitinib), allows to approach to personalized treatment of RA and the prevention of adverse outcomes. The widespread introduction of the subcutaneous form of methotrexate into clinical practice, a highly effective drug in relation to the activity and progression in early RA, well tolerated for a long time, allows to achieve the goal for most patients after 6-12 months of therapy using the principles of controlled treatment.

Full Text

Restricted Access

References

  1. Aletaha D., Neogi T., Silman A.J., et al. Rheumatoid Arthritis classification criteria / An American College of Rheumatology / European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62: 2569-81.
  2. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum. Dis. 2010: 69: 631-7.
  3. Breedveld F.C., Emery P., Keystone E. et al. Infliximab in active early rheumatoid arthritis. Ann. Rheum. Dis. 2004; 63: 149-55.
  4. Jantii J., Kaarela K., Belt E., et. al. Incidence of severe outcome in rheumatoid arthritis during 20 years. J. Rheumatol. 2002; 29: 688-92.
  5. Smolen J.S., Landewe R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum Dis. 2014; 73: 492-509.
  6. Насонов Е.Л., Мазуров В.И., Каратеев Д.Е. и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественное организации «Ассоциация ревматологов России» (часть 1). Научно-практ.ревматология. 2014; 5: 477-94.
  7. Emery P., Breedveld F.C., Hall S., et.al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, doubleblind, parallel treatment trial. Lancet. 2008; 372: 375-82.
  8. Nandi P., Kingsley G.H., Scott D.L. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis. Curr. Opin. Rheumatol. 2008; 20: 251-56.
  9. Plosker G.L., Croom K.F. Sulphasalazine: a review of its use in the management of rheumatoid arthritis Drugs. 2005; 65: 1825-49.
  10. Dougados M., Emery P., Lemmel E.M., et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIF 6-month data. J. Rheum. 2003; 30: 2672-579.
  11. Lard L.R., Visser H., Speyer I., et al. Early versus delayed treatment un patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med., 2001; 111: 446-51.
  12. Grigor C., Capell H., Stirling A., et al. Effect of treatment strategy of tight control of rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004; 364: 263-69.
  13. Korpela M., Laansonen L., Hannonen P., et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from FIN-RACo study. Arthr. Rheum. 2004; 50: 2072-81.
  14. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2007; 146: 406-15.
  15. Verstappen S.M.M., Jacobs J.W., van der Veen M.J., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 2007; 66: 1443-49.
  16. Bakker M.F., Jacobs W.C., Welsing P.M.J., et al. Early clinical response to treatment predict 5-year outcome in RA patients: follow-up results from the CAMERA st4. Ann. Rheum. Dis. 2011; 70: 1099-103.
  17. Chan E.S.L., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthr. Res. 2002; 4: 266-73.
  18. Donanue K.E., Gartlenhar G., Jonas D.E., et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann. Int. Med. 2008; 148: 124-34.
  19. Kuriya B., Arkema E.V., Bykerk V.P., Keystone E.C. Efficacy of initial methotrexate monotherapy versus combination therapy with biological agent in early rheumatoid arthritis: a metaanalysis of clinical and radiographic remission. Ann. Rheum. Dis. 2010; 69: 1298-304.
  20. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systemic literature research. Ann. Rheum. Dis. 2009; 68: 1100-104.
  21. Pincus T., Yazici Y., Sokka T., et al. Methotrexate as the «anchor drug» for the treatment of early rheumatoid arthritis. Clin. Exp. Rheum. 2003; 21(Supl. 31): S178-85.
  22. Visser K., van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis. 2009; 68: 1094-99.
  23. Visser K., Katchamart W., Loza J.A., et al. Multinational evidence-based recommendations for a use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3 E Initiative. Ann. Rheum. Dis. 2009; 68: 1086-93.
  24. Schiff M.H., Jaffe J.S., Freundlich B. Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at dose ≥15 mg may be overcome with subcutaneous administration. Ann. Rheum. Dis. 2014; 73: 1549-51.
  25. Braun J., Kastner P., Flaxenberg P., et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81.
  26. Scott D., Claydon P., Ellis C., Buchan S.A. Retrospective study of the effect of switching from oral to subcutaneous (SC) methoptrexate (MTX): the Methotrexate Evaluation of Norwich Treatment Outcomes in RA (MENTOR) study. British Soc Rheumatology, Glasgow, UK, 2012. P. 221.
  27. Hazlewood G., et al. Sucutaneous delivery of methotrexate is associated with improved treatment survival compared to oral administration of the initial treatment of patients with early rheumatoid arthritis. Arthritis Rheum. 2013; 65(Suppl. 10): 627.
  28. Liakos A., Batley M., Hammond T., et al. Subcutaneous methotrexate is more efficacious and better tolerated than oral methotrexate: the experience of a large group of patients in the Rheumatology department of a district general hospital. Ann. Rheum. Dis. 2012; 71(Supp. 3): 672.
  29. Mueller R., Schiff M.H., Haile S.R., von Kempis J. Effectiveness, tolerability, and safety of subcutaneous methotexate in early rheumatoid arthritis: clinical data from Dt. Gallen cohort. Ann. Rheum. Dis. 2014; 73 (Suppl2).
  30. Fotzpatric R., Scott D.G., Keary I. Cost-minimization analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who had have an insufficient response or intolerance to oral methotrexate. Clin. Rheumatol. 2013; 32: 1605-12.
  31. Shea B., Swinden M.V., Tanjong Ghogomi E., et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev. 2013; 5: CD000951. doi: 1002/14651858. CD000951.pub2
  32. Choi H.K., Herman M.A., Seeper J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002; 359: 1173-77.
  33. Assous N., Touze E., Meune C., et al. Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. Joint one Spine. 2007; 74: 66-72.
  34. Van Halm V.P., Nurmohamed M.T., Twisk J.W., et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case-control study. Arthritis Res. Ther. 2006; 8: R151.
  35. Maatzel A., Wong A., Strand V., et al. Metaanalysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2000; 39: 975-81.
  36. Salliot C., van der Heijde D. Long term safety of methotrexate monotherapy in rheumatoid arthritis patients: a systematic literature research. Ann. Rheum. Dis. 2009; 68: 1100-104.
  37. Mahr A.D., Jover J.A., Spiera R.F., et al. Adjunctive methotrexate for trestment of giant cell arteritis: an individual patient data metaanalysis. Arthritis. Rheum. 2007; 56: 2789-97.
  38. Ferraccioli G., Salafi F., De Vita, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J. Rheumatol. 1996; 23: 624-28.
  39. Caporali R., Cimmino M.A., Ferraccioli G., et al. Prednosoe plus methotrexate for polymyalgia rheumatic: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2004; 141: 493-500.
  40. Sany J., Anaja J.M., Canovas F., et al. Influence of methotrexate on the frequence of postoperative infectious complications in patients with rheumatoid arthritis. J. Rheumatol. 1993; 20: 1129-32.
  41. Grennan D.M., Gray J., Loudon J., Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann. Rheum. Dis. 2001; 60: 214-17.
  42. Carpenter M.T., West S.G., Vogelgesang S.A. Casey Jones DE. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics. 1996; 19: 207-10.
  43. Murata K., Yasuda T., Ito H., et al. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod. Rheumatol. 2006; 16: 14-9.
  44. Ostensen M., Hartmann H., Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J. Rheumatol. 2000; 27: 1872-75.
  45. Charakravarty E.F., Sanchez-Yamamoto D., Bush T.M. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J. Rheumatol. 2003; 30: 241-46.
  46. Felson D.T., Smolen J.S., Wells G., et al. American College of Rheumatology/European League Against Rheumatism Provisional Definition of remission in Rheumatoid Arthritis for clinical trials. Arthritis Rheum. 2011; 63: 573-86.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies